IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#1845
Positioning
Market Dominance
Manufacturing
Medical Equipment
$2.0B
James P. Mackin
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = AORT ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$AORT ARTIVION, INC. | 51 | 57 | 56 | 50 | 362.9x | 74.6x | 1.1% | 0.6% | 64.6% | 6.3% | 1.0% | 15.7% | 0.0% | 48.0x | $2.0B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
ARTIVION, INC. (AORT) receives a "Hold" rating with a composite score of 51.1/100. It ranks #1845 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
James P. Mackin
Chief Executive Officer
Labor Force
1,300
57
33
73
Audit Verdict: Average governance indicators based on financial metrics.
No recent insider transactions available for AORT
In-line with peers — no strong momentum signal
Fair valuation relative to peers
Average quality profile
Low volatility — smoother ride and historically better risk-adjusted returns
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for AORT.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
ROIC 19.5% vs WACC 9.0% (spread +10.5%)
GM 65% vs sector 43%, OM 6% vs sector 1%
Capital turnover 3.11x, R&D intensity 7.0%
Rev growth 16%, 10yr history
Interest coverage 5.5x, Net debt/EBITDA 4.2x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our model assigns ARTIVION, INC. a Hold rating, with a composite score of 51.1/100 and 3 out of 5 stars. Ranked #1845 of 7,333 stocks, AORT presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
With a quality score of 57/100, AORT shows adequate but unremarkable business quality. The company reports a return on equity of 1.1% (sector avg: -2.5%), gross margins of 64.6% (sector avg: 42.5%), net margins of 1.0% (sector avg: -0.2%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
AORT's value score of 56/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include a P/E ratio of 362.85x, an EV/EBITDA of 74.64x, a P/B ratio of 4.09x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
ARTIVION, INC.'s investment score of 33/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 15.7% vs. a sector average of 5.9% and a return on assets of 0.6% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
AORT demonstrates moderate momentum with a score of 50/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at 15.7% year-over-year, while a beta of 0.68 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
AORT shows good financial stability with a score of 73/100. Key stability metrics include a beta of 0.68 and a debt-to-equity ratio of 48.00x (sector avg: 0.2x). This suggests manageable leverage and moderate price volatility, making it appropriate for investors seeking a balance between growth potential and capital preservation.
ARTIVION, INC.'s short interest score of 36/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 48.00x), small-cap liquidity risk. At $2.0B (small-cap), AORT carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
ARTIVION, INC. is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #1845 of 7,333 overall (75th percentile). Key comparisons include ROE of 1.1% exceeding the -2.5% sector median and operating margins of 6.3% above the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While AORT currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Investment (33) is the limiting factor — improvement here would lift the composite score most.
EV/EBITDA 551% ABOVE SECTOR MEDIAN
ROE 146% BELOW SECTOR MEDIAN
Gross Margin 52% ABOVE SECTOR MEDIAN (FAVORABLE)
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate ARTIVION, INC. (AORT) as a Hold with a composite score of 51.1/100 at a current price of $35.36. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling for existing holders. Our factors are split, and the overall profile suggests patience is warranted.
The rating is primarily driven by strength in stability (73th percentile) and quality (57th percentile), which together account for the majority of the composite score. Offsetting weakness in investment (33th percentile) and momentum (50th percentile) tempers our overall conviction. We assign a Narrow Moat rating (56/100), Low uncertainty, and Poor capital allocation.
Key items to watch: quarterly earnings execution and sector-level competitive dynamics. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
ARTIVION, INC. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 51.1/100 places it at rank #1845 in our full 7,333-stock universe. At $2.0B in market capitalization, ARTIVION, INC. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue is growing at 16%, though momentum at the 50th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 65% (+22.1pp vs sector) narrow to operating margins of 6% (+5.0pp vs sector) and net margins of 1.0%, yielding a gross-to-net conversion rate of 2%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $35.36, ARTIVION, INC. is trading near fair value based on current fundamentals. Our value factor score of 56/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.
The stock currently trades at a P/E of 362.9x (a 1531% premium to the sector median of 22.3x), EV/EBITDA of 74.6x (at a premium), P/B of 4.1x, P/S of 4.3x. The above-sector P/E multiple suggests the market is pricing in superior growth or quality, which our analysis finds only partially justified by current fundamentals.
Gross margins of 65% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Revenue growth of 16% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
A P/E of 362.9x leaves little room for execution misses — any earnings disappointment could trigger a sharp multiple compression.
Thin net margins of 1.0% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
We assign a Low uncertainty rating to ARTIVION, INC.. The company exhibits strong financial stability with a beta of 0.68, conservative leverage (48% D/E), and a stability factor in the 73th percentile. The predictable nature of the business model and solid financial position reduce the range of potential outcomes, giving us confidence in our fair value estimate.
Specific risk factors that inform our assessment include: low beta of 0.68 — while defensive, this may indicate limited upside participation in bull markets; elevated valuation multiple (P/E 362.9x) that leaves limited margin for error. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 73th percentile and quality factor at the 57th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 65% provide a buffer against cost pressures; above-average stability (73th percentile) suggests predictable business dynamics. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile is favorable for long-term investors.
We rate ARTIVION, INC.'s capital allocation as Poor. Key concerns include low returns on equity (1.1%), weak asset returns (ROA 0.6%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — ARTIVION, INC. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, ARTIVION, INC. receives a Hold rating with a composite score of 51.1/100 (rank #1845 of 7,333). Our quantitative framework assigns a Narrow Moat (56/100, trend: stable), Low uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 54/100.
Our analysis supports a neutral stance on ARTIVION, INC.. While the quantitative profile is not weak enough to warrant selling, it lacks the multi-factor strength required for a buy recommendation. Existing holders should maintain positions and monitor for catalysts — either fundamental improvement or valuation compression — that would shift the risk-reward balance.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We assign ARTIVION, INC. a Narrow Moat rating with a composite moat score of 56/100. The ROIC-WACC spread of +10.5% is the primary signal of economic value creation. The company possesses identifiable competitive advantages, though they are less entrenched than those of wide-moat peers. Our analysis indicates that ARTIVION, INC. can sustain above-average returns on invested capital for at least 10 years, with the strongest contributor being margin superiority at 14.8/20.
The strongest moat sources are margin superiority (14.8/20) and growth durability (13.5/20). GM 65% vs sector 43%, OM 6% vs sector 1%. Rev growth 16%, 10yr history. These pillars form the core of ARTIVION, INC.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include financial resilience (8/20) and reinvestment efficiency (8.5/20). Interest coverage 5.5x, Net debt/EBITDA 4.2x. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect ARTIVION, INC.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 65% providing a solid profitability foundation, robust top-line growth of 16% expanding the revenue base. The margin cascade from 65% gross to 6% operating to 1.0% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality is adequate though not exceptional, with the quality factor at the 57th percentile.
The margin profile shows gross margins of 65%, operating margins of 6%, net margins of 1.0%. Return metrics include ROE of 1.1% and ROA of 0.6%. Relative to the Manufacturing sector, gross margins are 22.1 percentage points above the sector median of 43%, and ROE of 1.1% compares to a sector median of -2.5%.
The balance sheet reflects moderate leverage with D/E of 48%, revenue growth of 16%. The sector median D/E is 0%, putting ARTIVION, INC. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Artivion’s fourth quarter results were met with a negative market reaction, as revenue came in just below Wall Street’s expectations. Management attributed the quarter’s performance to robust demand for stent grafts, which grew 36% year-over-year, and continued gains from the On-X mechanical heart valve, which benefited from newly published clinical data. CEO Pat Mackin noted, “Growth was driven by our continued global market share gains and early traction in our new $100 million U.S. market opp

Artivion Inc, a cardiac and vascular solutions company, has received mixed analyst ratings with an average 12-month price target of $43.83. The company shows strong financial performance with impressive revenue growth, net margin, and efficient asset utilization.

AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Above 50MA
37.18%
Net New Highs
+51081